Telix Pharmaceuticals Limited (TLX) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $3.9B · $11.62 · 52-week range $6.28–$13.11

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-09-07	Smith Darren Charlton	officer: Group Chief Financial Officer	2,071	$9.66	$19,998	SEC Form 4
2026-04-29	Behrenbruch Christian	director, officer: MD & Group CEO	33,435	$14.87	$497,178	SEC Form 4
2026-04-28	Behrenbruch Christian	director, officer: MD & Group CEO	34,500	$14.48	$499,560	SEC Form 4

Financial health

Altman Z-Score 4.15 · Piotroski F-Score 4/9 · Cash $213M · Debt $700M

ClearOcean signal read

ClearOcean's model currently scores TLX as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — TLX Form 4
How ClearOcean reads insider activity

Last updated September 29, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.